Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
62 shown of 9,023 total abstracts
  1. Abstract 13892026-04-05 · 19:30 CT · Arie Crown Theater
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    J. Brahmer, A. Spira, H. Rugo, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  2. Abstract 17102026-04-02 · 14:15 CT · Arie Crown Theater
    IMpower-949: Tecentriq (atezolizumab) maintenance in TNBC
    C. Robert, H. Borghaei, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  3. Abstract 16452026-04-01 · 13:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-755
    F. Andre, T. Mok, S. Tolaney · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  4. Abstract 15922026-04-04 · 16:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-266
    S. Peters, S. Modi, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  5. Abstract 16072026-04-03 · 21:30 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-652
    C. Saura, H. Borghaei · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  6. Abstract 10382026-04-04 · 19:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-715 study)
    J. Brahmer, M. Reck · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  7. Abstract 12282026-04-04 · 16:45 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    P. Schmid, S. Antonia, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  8. Abstract 18892026-04-01 · 13:45 CT · S100A
    ASCENT-67: Trodelvy (sacituzumab govitecan) 2L in TNBC
    T. Mok, P. Schmid · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  9. Abstract 19622026-04-04 · 13:45 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-15
    T. Mok, S. Modi, M. Reck · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  10. Abstract 18212026-04-04 · 14:00 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-760 study)
    S. Peters, P. Schmid, J. Brahmer, et al. · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  11. Abstract 11982026-04-01 · 13:45 CT · E450
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-813
    P. Schmid, H. Rugo, R. Herbst · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  12. Abstract 15042026-04-03 · 18:30 CT · Hall B1
    MONARCH-874: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    P. Schmid, F. Andre, L. Paz-Ares, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  13. Abstract 13122026-04-03 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-198 study)
    S. Tolaney, S. Peters, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  14. Abstract 17972026-04-01 · 21:15 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-74
    S. Modi, J. Cortes, C. Saura · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  15. Abstract 10832026-04-01 · 14:30 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    M.C. Garassino, C. Robert, A. Spira, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  16. Abstract 12522026-04-02 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-900 study)
    E. Winer, H. Rugo, M.C. Garassino · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  17. Abstract 13092026-04-04 · 19:45 CT · S406
    DESTINY-Breast-2: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    M. Krop, H. Borghaei, T. Mok, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  18. Abstract 18112026-04-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-139
    L. Paz-Ares, J. Brahmer, A. Spira, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  19. Abstract 10522026-04-02 · 16:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-359 study)
    G. Curigliano, E. Winer, J. Cortes, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  20. Abstract 10392026-04-04 · 15:45 CT · E450
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-120
    T. Mok, C. Robert · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  21. Abstract 18672026-04-02 · 16:45 CT · Arie Crown Theater
    DESTINY-Breast-852: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    J. Cortes, S. Tolaney, S. Antonia, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  22. Abstract 18172026-04-01 · 15:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-159 study)
    P. Schmid, N. Rizvi, T. Mok, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  23. Abstract 12072026-04-02 · 14:15 CT · S406
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-262
    C. Robert, T. Mok, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  24. Abstract 11532026-04-02 · 20:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    J. Cortes, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  25. Abstract 10992026-04-03 · 13:00 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    S. Tolaney, M. Reck, J. Cortes, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  26. Abstract 12262026-04-01 · 13:30 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    H. Rugo, H. Borghaei, J. Brahmer · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  27. Abstract 15282026-04-01 · 18:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-88 study)
    E. Winer, S. Modi, T. Mok · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  28. Abstract 17252026-04-01 · 14:15 CT · Arie Crown Theater
    MONARCH-282: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    M. Reck, J. Cortes, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  29. Abstract 18072026-04-04 · 15:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-105
    H. Rugo, R. Herbst, M.C. Garassino · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  30. Abstract 12592026-04-02 · 16:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-738
    S. Peters, M. Reck, M. Krop · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  31. Abstract 12522026-04-05 · 14:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-440 study)
    J. Cortes, S. Peters, M. Reck, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  32. Abstract 17002026-04-04 · 19:00 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-784 study)
    H. Borghaei, T. Mok · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  33. Abstract 14662026-04-04 · 21:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-42
    S. Modi, H. Borghaei · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  34. Abstract 10672026-04-02 · 19:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-324 study)
    M. Reck, L. Paz-Ares, J. Cortes, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  35. Abstract 18582026-04-05 · 21:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-497
    P. Schmid, H. Rugo, S. Antonia, et al. · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  36. Abstract 14392026-04-05 · 15:45 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    J. Brahmer, S. Antonia · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  37. Abstract 14552026-04-03 · 14:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-341 study)
    R. Herbst, H. Rugo, H. Borghaei, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  38. Abstract 14482026-04-05 · 18:00 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-851
    H. Rugo, M. Krop, F. Andre, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  39. Abstract 16022026-04-04 · 18:00 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-122 study)
    L. Paz-Ares, G. Curigliano, M.C. Garassino, et al. · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  40. Abstract 14872026-04-05 · 13:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-33
    J. Brahmer, M. Krop, A. Spira, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  41. Abstract 18362026-04-04 · 15:45 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    G. Curigliano, J. Brahmer, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  42. Abstract 11582026-04-05 · 20:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-183 study)
    L. Paz-Ares, S. Peters, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  43. Abstract 12222026-04-04 · 15:00 CT · S100A
    MONARCH-337: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M.C. Garassino, H. Borghaei, R. Herbst, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  44. Abstract 14982026-04-03 · 14:45 CT · S406
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-353
    N. Rizvi, R. Herbst, T. Mok, et al. · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  45. Abstract 18842026-04-01 · 18:00 CT · E450
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-987
    N. Rizvi, S. Antonia, S. Peters · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  46. Abstract 15172026-04-03 · 16:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-58 study)
    S. Tolaney, S. Modi, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  47. Abstract 11002026-04-05 · 16:15 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    S. Peters, G. Curigliano, S. Tolaney · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 15202026-04-05 · 16:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-539 study)
    A. Spira, M. Reck, M. Krop · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  49. Abstract 15862026-04-02 · 13:00 CT · E450
    MONALEESA-359: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    L. Paz-Ares, J. Brahmer, T. Mok, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  50. Abstract 16622026-04-02 · 19:30 CT · E450
    MONALEESA-996: Kisqali (ribociclib) 2L in HR+ breast cancer
    J. Brahmer, N. Rizvi, E. Winer, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  51. Abstract 18462026-04-04 · 15:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-892
    G. Curigliano, H. Borghaei · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  52. Abstract 14702026-04-05 · 15:45 CT · Arie Crown Theater
    DESTINY-Breast-766: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    N. Rizvi, J. Cortes, S. Peters, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  53. Abstract 15072026-04-02 · 16:00 CT · S406
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-670
    J. Brahmer, S. Tolaney, C. Saura, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  54. Abstract 16032026-04-05 · 14:45 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-919
    H. Rugo, P. Schmid · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  55. Abstract 14002026-04-01 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-316
    M. Reck, T. Mok, M. Krop, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  56. Abstract 16192026-04-02 · 19:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-380
    F. Andre, A. Spira, S. Tolaney, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  57. Abstract 18362026-04-02 · 13:30 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Antonia, P. Schmid, R. Herbst, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  58. Abstract 11662026-04-03 · 20:30 CT · S406
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-196
    S. Antonia, C. Saura, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  59. Abstract 12062026-04-04 · 18:45 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-271
    S. Peters, S. Antonia, S. Modi · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  60. Abstract 15412026-04-03 · 13:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-887
    S. Antonia, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  61. Abstract 14222026-04-01 · 18:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-442
    C. Robert, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  62. Abstract 16772026-04-01 · 19:30 CT · Arie Crown Theater
    MONARCH-137: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    H. Rugo, C. Robert · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.